Halozyme Therapeutics (NASDAQ:HALO) Given New $65.00 Price Target at Wells Fargo & Company

Halozyme Therapeutics (NASDAQ:HALO) had its price objective hoisted by Wells Fargo & Company from $60.00 to $65.00 in a research report report published on Wednesday morning,Benzinga reports. They currently have an equal weight rating on the biopharmaceutical company’s stock.

HALO has been the topic of several other reports. JPMorgan Chase & Co. lifted their target price on shares of Halozyme Therapeutics from $55.00 to $58.00 and gave the stock a “neutral” rating in a research report on Monday, April 21st. Piper Sandler lifted their price objective on shares of Halozyme Therapeutics from $52.00 to $53.00 and gave the stock a “neutral” rating in a research report on Friday, January 10th. HC Wainwright restated a “buy” rating and issued a $72.00 target price on shares of Halozyme Therapeutics in a report on Friday, April 25th. Finally, Benchmark reissued a “buy” rating and set a $75.00 price target on shares of Halozyme Therapeutics in a research report on Thursday, February 20th. Five analysts have rated the stock with a hold rating and five have issued a buy rating to the stock. Based on data from MarketBeat, Halozyme Therapeutics currently has an average rating of “Moderate Buy” and an average target price of $63.78.

Halozyme Therapeutics Trading Down 2.8 %

Halozyme Therapeutics stock opened at $65.86 on Wednesday. The firm has a market cap of $8.14 billion, a price-to-earnings ratio of 19.20, a price-to-earnings-growth ratio of 0.42 and a beta of 1.26. Halozyme Therapeutics has a 1 year low of $42.01 and a 1 year high of $70.51. The firm’s 50 day moving average price is $61.45 and its two-hundred day moving average price is $55.80. The company has a debt-to-equity ratio of 4.14, a quick ratio of 9.15 and a current ratio of 7.80.

Halozyme Therapeutics (NASDAQ:HALO) last announced its earnings results on Tuesday, May 6th. The biopharmaceutical company reported $1.11 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.98 by $0.13. Halozyme Therapeutics had a return on equity of 157.78% and a net margin of 43.74%. The company had revenue of $264.86 million for the quarter, compared to analyst estimates of $231.21 million. During the same period in the previous year, the firm earned $0.79 earnings per share. Halozyme Therapeutics’s revenue for the quarter was up 35.2% compared to the same quarter last year. On average, research analysts predict that Halozyme Therapeutics will post 4.73 EPS for the current fiscal year.

Insider Activity at Halozyme Therapeutics

In other Halozyme Therapeutics news, Director Jeffrey William Henderson sold 5,000 shares of the business’s stock in a transaction dated Monday, March 3rd. The stock was sold at an average price of $58.69, for a total value of $293,450.00. Following the completion of the sale, the director now owns 33,611 shares of the company’s stock, valued at $1,972,629.59. The trade was a 12.95 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, SVP Michael J. Labarre sold 1,697 shares of the stock in a transaction dated Thursday, February 27th. The shares were sold at an average price of $58.28, for a total value of $98,901.16. Following the transaction, the senior vice president now directly owns 173,756 shares in the company, valued at approximately $10,126,499.68. This represents a 0.97 % decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 21,697 shares of company stock valued at $1,276,552. 2.90% of the stock is currently owned by corporate insiders.

Institutional Trading of Halozyme Therapeutics

Several large investors have recently modified their holdings of the company. Bessemer Group Inc. lifted its position in Halozyme Therapeutics by 62.9% during the 1st quarter. Bessemer Group Inc. now owns 536 shares of the biopharmaceutical company’s stock worth $34,000 after acquiring an additional 207 shares during the last quarter. CBIZ Investment Advisory Services LLC acquired a new position in shares of Halozyme Therapeutics during the 4th quarter worth about $29,000. Heck Capital Advisors LLC bought a new stake in Halozyme Therapeutics during the 4th quarter valued at approximately $29,000. Smartleaf Asset Management LLC grew its holdings in Halozyme Therapeutics by 29.2% in the 4th quarter. Smartleaf Asset Management LLC now owns 871 shares of the biopharmaceutical company’s stock valued at $42,000 after buying an additional 197 shares during the last quarter. Finally, Park Place Capital Corp increased its position in Halozyme Therapeutics by 20.1% in the 1st quarter. Park Place Capital Corp now owns 1,086 shares of the biopharmaceutical company’s stock worth $69,000 after buying an additional 182 shares during the period. 97.79% of the stock is owned by institutional investors.

Halozyme Therapeutics Company Profile

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.